Perrigo Company has received final FDA approval for abbreviated new drug application for generic equivalent to cutivate lotion, 0.05% and begins immediate shipment of the product.
Cutivate Lotion 0.05% (fluticasone propionate lotion, 0.05%) is indicated to relieve the inflammatory and pruritic manifestations of atopic dermatitis in patients aged one year and more.
Perrigo chairman and CEO Joseph Papa said, "This is another example of our Rx team's commitment to launching difficult to manufacture topicals, lotions and foams."
The company develops, manufactures and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/us-fda-clears-perrigos-generic-equivalent-to-cutivate-lotion-005-020813
